WHO provides first-ever approval for rectal artesunate product for severe malaria

Medicines for Malaria Venture (MMV), 27 February 2018

Read online at:

On 22 February 2018, Indian pharmaceutical company Cipla Ltd. received confirmation of approval from the World Health Organization (WHO) Prequalification Programme for their 100 mg rectal artesunate suppositories (RAS) for the pre-referral management of severe malaria. The much-awaited approval, achieved with support from Medicines for Malaria Venture (MMV) and funding from Unitaid, makes the Cipla product the first to receive prequalification for this indication. Importantly, prequalification will enable countries to procure life-saving RAS, thus ensuring the product’s greater uptake and distribution.

(Visited 17 times, 1 visits today)
This entry was posted in Essential Medicines, General, Malaria, Maternal & Child Health. Bookmark the permalink.